|
Name |
(11R)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one
|
| Molecular Formula | C18H26O4 | |
| IUPAC Name* |
(4R)-16,18-dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-2-one
|
|
| SMILES |
C[C@@H]1CCCCCCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1
|
|
| InChI |
InChI=1S/C18H26O4/c1-13-9-7-5-3-2-4-6-8-10-14-11-15(19)12-16(20)17(14)18(21)22-13/h11-13,19-20H,2-10H2,1H3/t13-/m1/s1
|
|
| InChIKey |
NPMCCMIBMODCMD-CYBMUJFWSA-N
|
|
| Synonyms |
(R)-Zearalane; (11R)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one; 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-, (3R)-
|
|
| CAS | NA | |
| PubChem CID | 5275921 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 306.4 | ALogp: | 6.0 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
| Heavy Atoms: | 22 | QED Weighted: | 0.671 |
| Caco-2 Permeability: | -4.847 | MDCK Permeability: | 0.00003270 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.999 |
| 30% Bioavailability (F30%): | 0.99 |
| Blood-Brain-Barrier Penetration (BBB): | 0.43 | Plasma Protein Binding (PPB): | 98.39% |
| Volume Distribution (VD): | 1.715 | Fu: | 1.52% |
| CYP1A2-inhibitor: | 0.953 | CYP1A2-substrate: | 0.189 |
| CYP2C19-inhibitor: | 0.887 | CYP2C19-substrate: | 0.068 |
| CYP2C9-inhibitor: | 0.55 | CYP2C9-substrate: | 0.97 |
| CYP2D6-inhibitor: | 0.922 | CYP2D6-substrate: | 0.316 |
| CYP3A4-inhibitor: | 0.492 | CYP3A4-substrate: | 0.062 |
| Clearance (CL): | 7.172 | Half-life (T1/2): | 0.545 |
| hERG Blockers: | 0.033 | Human Hepatotoxicity (H-HT): | 0.091 |
| Drug-inuced Liver Injury (DILI): | 0.433 | AMES Toxicity: | 0.09 |
| Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.799 |
| Skin Sensitization: | 0.936 | Carcinogencity: | 0.11 |
| Eye Corrosion: | 0.134 | Eye Irritation: | 0.965 |
| Respiratory Toxicity: | 0.546 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005003 | ![]() |
0.903 | D07GRH | ![]() |
0.284 | ||
| ENC002297 | ![]() |
0.903 | D08VSI | ![]() |
0.275 | ||
| ENC005007 | ![]() |
0.775 | D0P6VV | ![]() |
0.270 | ||
| ENC005005 | ![]() |
0.704 | D07MGA | ![]() |
0.268 | ||
| ENC005004 | ![]() |
0.704 | D00ZFP | ![]() |
0.253 | ||
| ENC002298 | ![]() |
0.704 | D03YVO | ![]() |
0.248 | ||
| ENC003244 | ![]() |
0.690 | D04JHN | ![]() |
0.245 | ||
| ENC002701 | ![]() |
0.690 | D0T3HY | ![]() |
0.245 | ||
| ENC003158 | ![]() |
0.667 | D0S5NG | ![]() |
0.243 | ||
| ENC003872 | ![]() |
0.644 | D0PG8O | ![]() |
0.243 | ||